Evolution for a cell-penetrating peptide that inhibits the interaction between core and surface prot

• 作 者: Xiao-ben PAN Lai WEI Jin-chao HAN Yan GAO Dan-dan PENG
• 机 构: Hepatology Institute Peking University People's Hospital, Beijing 100044 P.R.China
• 出 处: 2008病毒性肝炎成就与挑战国际研讨会(International Confernece on Viral Hepati
• 发表日期: 2008年1期
• 关键词: Hepatitis virus B Cell penetrating peptide Antivirus Core protein

　　Human hepatitis B virus (HBV) infects chronically over 350 million people globally, and these chronic HBV carriers are at risk of developing cirrhosis and hepatocellular carcinoma.Currently, interferon-α and nucleoside analogs such as lamivudine and adefovir dipivoxil have been approved for the treatment of HBV, whereas the IFN is effective only in less than 30% of the chronic carriers, and substantial resistance to nucleoside analogs during the slow phase of HBV elimination limits its long-term treatment of HBV infection.